Antiviral oligonucleotides

Details Antiviral oligonucleotides Antiviral oligonucleotides

2008-04-15

2008-04-15

Campell, Bruce R. (Department: 1648)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Preparing compound containing saccharide radical

C435S006120

Reexamination Certificate

active

07358068

ABSTRACT:
Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.

REFERENCES:
patent: 3687808 (1972-08-01), Merigan, Jr. et al.
patent: 4426330 (1984-01-01), Sears
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4534899 (1985-08-01), Sears
patent: 4615697 (1986-10-01), Robinson
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5023252 (1991-06-01), Hseih
patent: 5130302 (1992-07-01), Spielvogel et al.
patent: 5177198 (1993-01-01), Spielvogel et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5218103 (1993-06-01), Caruthers et al.
patent: 5223618 (1993-06-01), Cook et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5248670 (1993-09-01), Draper et al.
patent: 5256775 (1993-10-01), Froehler
patent: 5264221 (1993-11-01), Tagawa et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5264562 (1993-11-01), Matteucci
patent: 5264564 (1993-11-01), Matteucci
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5278302 (1994-01-01), Caruthers et al.
patent: 5356633 (1994-10-01), Woodle et al.
patent: 5366878 (1994-11-01), Pederson et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5386023 (1995-01-01), Sanghvi et al.
patent: 5452496 (1995-09-01), Long et al.
patent: 5476925 (1995-12-01), Letsinger et al.
patent: 5489677 (1996-02-01), Sanghvi et al.
patent: 5508270 (1996-04-01), Baxter et al.
patent: 5514788 (1996-05-01), Bennett et al.
patent: 5540935 (1996-07-01), Miyazaki et al.
patent: 5543152 (1996-08-01), Webb et al.
patent: 5556948 (1996-09-01), Tagawa et al.
patent: 5563050 (1996-10-01), Peyman et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5591623 (1997-01-01), Bennett et al.
patent: 5591720 (1997-01-01), Anderson et al.
patent: 5591721 (1997-01-01), Agrawal et al.
patent: 5602244 (1997-02-01), Caruthers et al.
patent: 5610289 (1997-03-01), Cook et al.
patent: 5625050 (1997-04-01), Beaton et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5670634 (1997-09-01), Marotta et al.
patent: 5684148 (1997-11-01), Caruthers et al.
patent: 5695979 (1997-12-01), Caruthers et al.
patent: 5705188 (1998-01-01), Junichi et al.
patent: 5750666 (1998-05-01), Caruthers et al.
patent: 5770713 (1998-06-01), Imbach et al.
patent: 5837449 (1998-11-01), Monia et al.
patent: 5952490 (1999-09-01), Hanecak et al.
patent: 5998602 (1999-12-01), Torrence et al.
patent: 6013240 (2000-01-01), Behr et al.
patent: 6013639 (2000-01-01), Peyman et al.
patent: 6143881 (2000-11-01), Metelev et al.
patent: 6177246 (2001-01-01), Monia et al.
patent: 6184369 (2001-02-01), Rando et al.
patent: 6316190 (2001-11-01), Rein et al.
patent: 6346614 (2002-02-01), Metelev et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6573099 (2003-06-01), Graham
patent: 6608035 (2003-08-01), Agrawal et al.
patent: 2003/0119019 (2003-06-01), Winnacker et al.
patent: 2003/0162225 (2003-08-01), James et al.
patent: 2003/0232435 (2003-12-01), Dobie
patent: 0 445 131 (1990-05-01), None
patent: 0 496 813 (1991-02-01), None
patent: WO 90/04384 (1990-05-01), None
patent: WO 91/05545 (1991-05-01), None
patent: WO 92/03051 (1992-03-01), None
patent: WO 94/02499 (1994-02-01), None
patent: WO 94/17093 (1994-08-01), None
patent: WO 94/20073 (1994-09-01), None
patent: WO 94/26764 (1994-11-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/40062 (1996-12-01), None
patent: WO 97/04787 (1997-02-01), None
patent: WO 97/13499 (1997-04-01), None
patent: WO 97/30731 (1997-08-01), None
patent: WO 98/39352 (1998-09-01), None
patent: WO 99/14226 (1999-03-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 02/68582 (2002-06-01), None
patent: WO 03/002903 (2003-01-01), None
patent: WO 03/097661 (2003-11-01), None
patent: WO 2004/002419 (2004-01-01), None
Andreola et al., Towards the selection of phosphorothioate aptamers optimizing in vitro selection steps with phosphorothioate nucleotides, European Journal of Biochemistry, 267, p. 5032-5040, Feb. 2000.
Agrawal and Kandimalla, “Antisense and/or Immunostimulatory Oligonucleotide Therapeutics,”Current Cancer Drug Targets1:197-209 (2001).
Allen and Chonn, “Large Unilamellar Liposomes with Low Uptake into the Reticuloendothelial System,”FEBS Letters223(1):42-46 (1987).
Archambault, et al., “Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses,”Arch Virol139:97-109 (1994).
Berkow, et al., “Nonsteroidal Anti-Inflammatory Drugs (NSAIDs),”The Merck Manual of Diagnosis and Therapy, 15thed., 2499-2506 and 46-49 (1987).
Blume and Cevc, “Liposomes for the sustained drug release in vivo,”Biochimica et Biophysica Acta1029:91-97 (1990).
Brunton, “Section VI Drugs Affecting Gastrointestinal Function,”The Pharmacological Basis of Therapeutics9(38):934-935 (1996).
Buur, et al., “Penetration of 5-Fluorouracil and Prodrugs Across the Intestine of the Albino Rabbit: Evidence for Shift in Absorption Site from the Upper to the Lower Region of the Gastrointestinal Tract by Prodrugs,”Journ. of Controlled Release14:43-51 (1990).
Campbell and Rein, “In Vitro Assembly Properties of Human Immunodeficiency Virus Type 1 Gag Protein Lacking the p6 Domain,”Journ. of Virol. 73:2270-2279 (1999).
Cevc, et al., “Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin,”Biochimica et Biophysica Acta1368:201-215 (1998).
Cheng, et al., “Interactions Between Single-Stranded DNA Binding Protein and Oligonucleotide Analogs with Different Backbone Chemistries,”Journ. Mol. Recognition10:101-107 (1997).
Constantinides, et al., “Formulation and Intestinal Absorption Enhancement Evaluation of Water-in-Oil Microemulsions Incorporating Medium-Chain Glycerides,”Pharmaceutical Res. 11:1385-1390 (1994).
Crooke, et al., “Pharacokinetic Properties of Several Novel Oligonucleotide Analogs in mice,”Journ. Pharm. and Experim. Therap. 277(2):923-937 (1996).
Crooke, S., “Progress in Antisense Technology: The End of the Beginning,”Meth. in Enzym. 313:3-45 (1999).
Du Plessis, et al., “Topical Delivery of Liposomally Encapsulated Gamma-Interferon,”Antivir. Res. 18:259-265 (1992).
El-Hariri, et al., “The Mitigating Effects of Phosphatidylcholines on Bile Salt- and Lysophosphatidylcholine-induced Membrane Damage,”J. Pharm. Pharmacol. 44:651-654 (1992).
Englisch and Gauss, “Chemically Modified Oligonucleotides as Probes and Inhibitors,”Angewandte Chemie30(6):613-722 (1991).
Feng, et al., “Reversible Binding of Recombinant Human Immunodeficiency Virus Type 1 Gag Protein to Nucleic Acids in Virus-Like Particle Assembly In Vitro,”Journ. of Virol. 76(22):11757-11762 (2002).
Fennewald, et al., “Inhibition of herpes simplex virus in culture by oligonucleotides composed entirely of deoxyguanosine and thymidine,”Antiviral Res. 26:37-54 (1995).
Gabison, et al., “Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors,”Proc. Natl. Acad. Sci. USA 85:6949-6953 (1988).
Goa, et al., “Effect of Phosphorothioate Homo-oligodeoxynucleotides on Herpes Simplex Virus Type 2-induced DNA Polymerase,ȁ

Affiliated with

Also associated with

Rating

Antiviral oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antiviral oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2763551